Biolife solutions stock.

Broadridge Corporate Issuer Solutions, Inc. P.O. Box 1342 Brentwood, New York 11717 USA (877) 830 - 4936 [email protected] Solutions, Inc. (NASDAQ:BLFS) Q3 2023 Earnings Call Transcript November 9, 2023 BioLife Solutions, Inc. beats earnings expectations. Reported EPS is $-0.3, expectations were $-0.38. Operator: Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to the BioLife Solutions Third Quarter 2023 Shareholder and …BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.BioLife Solutions GAAP EPS of -$0.17 beats by $0.09, revenue of $36.22M misses by $1.98M SA News Mon, May 09, 2022 BioLife Solutions gains as Oppenheimer upgrades on valuation

BioLife Solutions: Overcoming Challenges and Primed for Growth – An Optimistic Buy Recommendation Amid Revenue Surpassing Expectations and Anticipated Divestiture TipRanks 18dSupplier: BIOLIFE SOLUTIONS INC 210373. This item has a minimum qty of 4 per supplier requirements. The CryoStor series of cell-specific, optimized freeze media, is designed to prepare and preserve cells in ultra low temperature environments (-70C to -196C). CryoStor CS10, pre-formulated with 10% DMSO, provides a safe, protective environment ...Webull offers BioLife Solutions Inc stock information, including NASDAQ: BLFS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BLFS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for …

Cold Chain Solutions. Cold Chain Shippers. ... Stock. CONTACT. BioLife Solutions Inc. 3303 Monte Villa Parkway, Suite 310, Bothell, WA 98021 USA ...BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapy (CGT) and broader biopharma markets, today announced ...

Nov 28, 2023 · BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. May 10, 2023 · BioLife Solutions Reports First Quarter 2023 Financial Results. Revenue of $37.7 million increased 4% over Q1 2022, ex-COVID growth of 16% and biopreservation media revenue growth of 28%. Q1 2023 ... Investing in the stock market takes a lot of courage, a lot of research, and a lot of wisdom. One of the most important steps is understanding how a stock has performed in the past. Of course, the past is not a guarantee of future performan...The estimated net worth of Andrew G. Hinson is at least $207,858.00 as of June 15th, 2021. Mr. Hinson owns 17,675 shares of BioLife Solutions stock worth more than $207,858 as of November 3rd. This net worth approximation does not reflect any other investments that Mr. Hinson may own. Learn More about Andrew G. Hinson's net worth.BioLife will issue 6,646,870 shares of common stock for 100% of the outstanding shares of Stirling in an all-stock transaction, which is expected to close early in the second quarter of 2021. With Stirling, BioLife believes that total GAAP revenue in 2021 will exceed $100 million and the transaction is expected to be accretive on an adjusted ...

Athens, Ohio, March 22, 2021 — Stirling Ultracold, a privately-held innovative developer and manufacturer of ultra-low temperature (ULT) freezers, today announced it has signed a definitive agreement to merge into BioLife Solutions (NASDAQ: BLFS) to combine expertise and expand individual product offerings for biopharma research and life ...

Aug 8, 2023 · BioLife Solutions, Inc. (BLFS) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $1.71 per share a year ago.

of class-defining solutions. Solutions. Our platforms enable significant improvement in shelf life and post-preservation viability and function of biologic materials. Cell Processing. ... BioLife Solutions Inc. 3303 Monte Villa Parkway, Suite 310, Bothell, WA 98021 USA; T +1.866.424.6543 or 425.402.1400; F +1.425.402.1433 ...BioLife Solutions is updating 2023 revenue guidance, which is based on expectations for its existing business. Total revenue for 2023 is expected to range from $144 million to $158 million ...Stock analysis for BioLife Solutions Inc (BLFS:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.May 9, 2023 · Biolife Solutions will release earnings for Q1 on May 10. Wall Street predict expect Biolife Solutions will release losses per share of $0.213. Go here to watch Biolife Solutions stock price in ... Dec 1, 2023 · msn.com - November 17 at 10:30 PM. BioLife Solutions (BLFS) was Impacted by Inventory Destocking and Elongated Sales Cycles. finance.yahoo.com - November 16 at 10:07 AM. Analysts Just Shaved Their BioLife Solutions, Inc. (NASDAQ:BLFS) Forecasts Dramatically. finance.yahoo.com - November 16 at 10:07 AM.

BioLife Solutions, Inc. Common Stock (BLFS) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Investing in the stock market takes a lot of courage, a lot of research, and a lot of wisdom. One of the most important steps is understanding how a stock has performed in the past. Of course, the past is not a guarantee of future performan...Oct 16, 2023 · BioLife Solutions to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 16, 2023. BOTHELL, Wash. , March 9, 2023 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and... Shareholder Director Nominations. The Board of Directors of BioLife Solutions, Inc., a Delaware corporation, (the " Company ") determined that the Company's 2023 Annual Meeting of Stockholders (the " Annual Meeting ") will be held on July 21, 2023. It is expected that the Annual Meeting will be held virtually on the internet, but the time and ...Open 18.44. Day High 18.95. Day Low 18.17. Prev Close 18.25. 52 Week High 26.96. 52 Week High Date 09/08/22. 52 Week Low 10.40. 52 Week Low Date 05/12/22. Market Cap 812.385M.

BOTHELL, Wash., Aug. 9, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies ("CGT") and the broader biopharma markets, today announced financial results for the three and six months ended ...

7 dic 2020 ... Thomas Girschweiler sold 1600000 shares, an approximate value of $36 million, of the BioLife Solutions' stock to Casdin Capital LLC.BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of 29.17% and 4.36%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?Oct 16, 2023 · BioLife Solutions to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 16, 2023. BOTHELL, Wash. , March 9, 2023 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and... Nov 24, 2023 · The BioLife Solutions stock price fell by -6.21% on the last day (Wednesday, 18th Oct 2023) from $12.39 to $11.62. During the last trading day the stock fluctuated 5.35% from a day low at $11.59 to a day high of $12.21. The price has fallen in 5 of the last 10 days and is down by -14.5% for this period. Volume fell on the last day along with ... Nov 15, 2023. Currency in USD. Quote data delayed by at least 15 minutes. Earnings and Analyst data provided by Zacks. Insiders data provided by Morningstar. CONTACT.

BLFS BioLife Solutions stock chart. #fintwits #money #wallstreet #stockmarket #stocks. 0 points. 1 comment. 1. 0 comments. share. save. 2. Posted by 2 years ago. I want to buy a trading bot, any recommendations here? 2. 3 comments. share. save. 1. Posted by 2 years ago. Adam Khoo FX trading. Hello! I got some courses a while back and have ...

Get the latest BioLife Solutions Inc (BLFS) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment …

(RTTNews) - Today's Daily Dose brings you news about FDA panel's stance on Akcea's drug candidate for a rare lipid disorder called familial chylom...BioLife Solutions, Inc. (BLFS) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to break-even earnings per share a year ago.Get the latest BioLife Solutions Inc (BLFS) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment …We are revolutionizing regenerative medicine, biobanking and drug discovery by increasing the viability of biologics. BioLife Solutions is a class-defining cell and gene therapy bioproduction tools and services company. Our solutions give life science companies and clinical researchers significant improvement in shelf life and post-preservation ...BOTHELL, Wash., Jan. 17, 2023 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapy (CGT) and the broader biopharma markets, today announced the dates of its 2023 analyst day and …BioLife Solutions Inc. Watch NEW Set a price target alert After Hours Last Updated: Nov 24, 2023 4:04 p.m. EST Delayed quote $ 14.00 -0.08 -0.57% After Hours Volume: 1.96K …BOTHELL, Wash., July 7, 2020 / PRNewswire / -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today announced the closing of its public offering of 5,951,250 shares of common stock at the public offering price ...The estimated net worth of Marcus Schulz is at least $465,171.85 as of August 25th, 2023. Mr. Schulz owns 42,097 shares of BioLife Solutions stock worth more than $465,172 as of November 2nd. This net worth approximation does not reflect any other investments that Mr. Schulz may own. Learn More about Marcus Schulz's net worth.100mL Bag. 205202. $545.00. Add to Cart. Note: A $200 minimum spend is required to checkout. Optimized Freeze Media for Cells and Tissues. CryoStor® proprietary freeze media products are intended for cryopreservation of biologics at -70 to -196°C. All CryoStor products are pre-formulated with USP-grade DMSO, a permeating cryoprotective agent ...BioLife Sciences is a commercialization accelerator, licensor and developer of innovative and disruptive technologies for the healthcare, beauty and food and beverage industry sectors. 2831 Saint Rose Parkway Suite 200 Henderson, NV 89052 United StatesBLFS: Raising target price to $10.00 BIOLIFE SOLUTIONS INC has an Investment Rating of SELL; a target price of $10.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety...Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and BLFS is experiencing ...

CryoStor®CS10 effectively mitigates temperature-induced molecular cell stress responses to maximize post-thaw viability and recovery for a variety of immune cell types, including T cells (data not shown) and B cells. Here, human B cells from 6 different donors cryopreserved in CryoStor®CS10 show reproducibly high viability after thawing, as ...5 Wall Street analysts have issued 1 year target prices for BioLife Solutions' stock. Their BLFS share price targets range from $22.00 to $28.00. On average, they expect the company's stock price to reach $24.60 in the next year. This suggests a possible upside of 91.7% from the stock's current price. View analysts price targets for BLFS or ... Name. Chg %. Market Cap. Evogene Ltd. -1.07%. $30.17M. BLFS | Complete BioLife Solutions Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial...Aug 11, 2023 · Shares of BioLife Solutions (BLFS 7.11%) were down more than 37% for the week, as of 3:15 p.m. ET on Friday, ... The healthcare company's stock closed last week at $19.22, then dropped to a 52 ... Instagram:https://instagram. stock websites to usecrude etfautomated crypto tradingtop ten wealth management firms Cold Chain Solutions. Cold Chain Shippers. ... Stock. CONTACT. BioLife Solutions Inc. 3303 Monte Villa Parkway, Suite 310, Bothell, WA 98021 USA ...Total revenue for the third quarter of 2023 was $33.3 million, a decrease of $7.4 million, or 18%, from $40.7 million for the third quarter of 2022. There was no COVID related revenue in the third ... private dental insurance oregonultra high net worth wealth management firms The latest closing stock price for BioLife Solutions as of November 24, 2023 is 14.08. The all-time high BioLife Solutions stock closing price was 140.00 on December 15, 1992. The BioLife Solutions 52-week high stock price is 26.89, … onfolio BioLife recently disclosed its financial results for the fourth quarter of 2022, showcasing solid revenue growth and a better gross margin. In Q4 2022, the company brought in $44.3 million in ...BioLife Solutions (BLFS) In a report released today, Robert Wasserman from Benchmark Co. maintained a Hold rating on BioLife Solutions. The company’s shares closed last Thursday at $11.96.